Source: Pharamceutical Technology

Biohaven: FDA grants Fast Track status for Biohaven's taldefgrobep alfa to treat SMA

Taldefgrobep alfa works as a receptor antagonist to block myostatin signalling in skeletal muscles. The post FDA grants Fast Track status for Biohaven's taldefgrobep alfa to treat SMA appeared first on Pharmaceutical Technology.

Read full article »

Biohaven's Competitors | Biohaven's News | Biohaven's Financials

Followers on Owler

Est. Annual Revenue

$500M-1.0B

Est. Employees

500-1.0K

CEO

Vlad Coric

CEO Approval Rating

92/100

Biohaven is a Connecticut-based pharmaceutical company that researches and develops novel drugs for the treatment of neurological and neuropsychiatric diseases.